In Part I of this three-part series, we focused on three mRNA technology market players: BioNTech, Moderna and CureVac. In this second post, we will focus on Translate BIO, Arcturus Therapeutics, and eTheRNA and discuss...more
Founders of an emerging company must decide early on in its growth cycle whether to require employees to assign their inventions (including rights to patent and patent applications –collectively “patent rights”) to the...more
3/29/2021
/ Artificial Intelligence ,
Assignments ,
Confidential Information ,
Fiduciary Duty ,
Intellectual Property Protection ,
Inventors ,
Joint Inventors ,
Patent Applications ,
Patents ,
Trade Secrets ,
USPTO
Moderna, one of the global leaders in developing a safe and effective vaccine to combat COVID-19, appears poised to get through clinical trials with a vaccine that is based on mRNA technology. As was recently announced,...more
11/16/2020
/ Coronavirus/COVID-19 ,
Final Written Decisions ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Moderna Inc. ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Popular ,
USPTO ,
Vaccinations
Last month, Moderna Therapeutics, one of the global leaders in the race to produce a COVID-19 vaccine, made the following statement regarding enforcement of its patents:
We feel a special obligation under the current...more
11/10/2020
/ Bayh-Dole Act ,
Biotechnology ,
Coronavirus/COVID-19 ,
Department of Defense (DOD) ,
European Commission ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Moderna Inc. ,
Patent Invalidity ,
Patent Ownership ,
Patents ,
Pharmaceutical Patents ,
Popular ,
Research and Development ,
USPTO ,
Vaccinations